DBV Technologies reported $13.8M in Trade Creditors for its fiscal quarter ending in September of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 16.33M 28.24M Sep/2026
Alnylam Pharmaceuticals USD 135.4M 27.38M Sep/2026
Amarin USD 40.43M 21.63M Sep/2026
BioCryst Pharmaceuticals USD 14.58M 3.12M Sep/2026
BioMarin Pharmaceutical USD 946.11M 32.44M Sep/2026
DBV Technologies USD 13.8M 25.7M Sep/2026
Galectin Therapeutics USD 3.7M 99K Jun/2024
Halozyme Therapeutics USD 33.55M 9.94M Sep/2026
Incyte USD 235.37M 1.16B Sep/2026
Insmed USD 84.3M 9.75M Sep/2026
Ionis Pharmaceuticals USD 27.11M 20.59M Sep/2026
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
PTC Therapeutics USD 41.59M 1.14M Sep/2026
Sarepta Therapeutics USD 45.7M 5.28M Sep/2026
Ultragenyx Pharmaceutical USD 45M 6M Sep/2026
United Therapeutics USD 520.2M 22.4M Sep/2026